Anticancer effect of a curcumin derivative B63: ROS production and mitochondrial dysfunction

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Curcumin, a natural polyphenol from Curcuma longa, exhibits chemotherapeutic and chemopreventive properties against various cancers, including colorectal cancer.
• Developing more potent analogues of curcumin is crucial for enhancing its therapeutic efficacy and bioavailability.

Purpose of the Study:

• To evaluate the anticancer potential of B63, a synthesized mono-carbonyl analogue of curcumin, in colorectal cancer.
• To compare the efficacy of B63 with curcumin and elucidate its mechanism of action in colon cancer cells.

Main Methods:

• In vitro assays were performed to assess the anti-proliferative effects, apoptosis, necrosis, and cell cycle arrest induced by B63 in colon cancer cells (SW620).
• Western blotting was used to analyze the expression of pro-apoptotic proteins (Bad, Bim) and the activation of caspases.
• Mitochondrial function, reactive oxygen species (ROS) generation, and endoplasmic reticulum (ER) stress were investigated.
• In vivo efficacy was evaluated using a mouse xenograft model.

Main Results:

• B63 demonstrated approximately double the anti-proliferative potency of curcumin in colon cancer cells (based on IC50 values).
• B63 induced significant necrosis, apoptosis, and S phase cell cycle arrest in SW620 cells, upregulating Bad and Bim, and promoting caspase-3 and PARP-1 cleavage.
• The anticancer activity of B63 was linked to increased intracellular ROS from mitochondrial dysfunction and induced ER stress.
• In vivo, B63 (50 mg/kg) exhibited comparable tumor growth inhibition to curcumin (100 mg/kg) in a mouse xenograft model.

Conclusions:

• The curcumin derivative B63 possesses superior anticancer capacity compared to curcumin in colon cancer.
• B63 mediates its cytotoxic effects through ROS generation, mitochondrial dysfunction, and ER stress, leading to apoptosis and necrosis.
• B63 represents a promising therapeutic agent for colorectal cancer with enhanced efficacy and a well-defined mechanism of action.